350 related articles for article (PubMed ID: 19597003)
1. Obstacles to the successful development of an efficacious T cell-inducing HIV-1 vaccine.
Haut LH; Ertl HC
J Leukoc Biol; 2009 Oct; 86(4):779-93. PubMed ID: 19597003
[TBL] [Abstract][Full Text] [Related]
2. No acquisition: a new ambition for HIV vaccine development?
Lakhashe SK; Silvestri G; Ruprecht RM
Curr Opin Virol; 2011 Oct; 1(4):246-53. PubMed ID: 22081778
[TBL] [Abstract][Full Text] [Related]
3. STEP trial and HIV-1 vaccines inducing T-cell responses.
Hanke T
Expert Rev Vaccines; 2008 Apr; 7(3):303-9. PubMed ID: 18393600
[TBL] [Abstract][Full Text] [Related]
4. Priming immunization with DNA augments immunogenicity of recombinant adenoviral vectors for both HIV-1 specific antibody and T-cell responses.
Koup RA; Roederer M; Lamoreaux L; Fischer J; Novik L; Nason MC; Larkin BD; Enama ME; Ledgerwood JE; Bailer RT; Mascola JR; Nabel GJ; Graham BS; ;
PLoS One; 2010 Feb; 5(2):e9015. PubMed ID: 20126394
[TBL] [Abstract][Full Text] [Related]
5. Use of adenovirus in vaccines for HIV.
Patterson S; Papagatsias T; Benlahrech A
Handb Exp Pharmacol; 2009; (188):275-93. PubMed ID: 19031031
[TBL] [Abstract][Full Text] [Related]
6. HIV-1 T-cell vaccines: evaluating the next step.
Pantaleo G
Lancet Infect Dis; 2008 Feb; 8(2):82-3. PubMed ID: 18060842
[No Abstract] [Full Text] [Related]
7. Modulation of Vaccine-Induced CD4 T Cell Functional Profiles by Changes in Components of HIV Vaccine Regimens in Humans.
Pissani F; Schulte B; Eller MA; Schultz BT; Ratto-Kim S; Marovich M; Thongcharoen P; Sriplienchan S; Rerks-Ngarm S; Pitisuttithum P; Esser S; Alter G; Robb ML; Kim JH; Michael NL; Streeck H
J Virol; 2018 Dec; 92(23):. PubMed ID: 30209165
[TBL] [Abstract][Full Text] [Related]
8. Prospects for a globally effective HIV-1 vaccine.
Excler JL; Robb ML; Kim JH
Vaccine; 2015 Nov; 33 Suppl 4():D4-12. PubMed ID: 26100921
[TBL] [Abstract][Full Text] [Related]
9. Progress in HIV vaccine development.
Hsu DC; O'Connell RJ
Hum Vaccin Immunother; 2017 May; 13(5):1018-1030. PubMed ID: 28281871
[TBL] [Abstract][Full Text] [Related]
10. HIV vaccine efficacy trials: towards the future of HIV prevention.
Kim D; Elizaga M; Duerr A
Infect Dis Clin North Am; 2007 Mar; 21(1):201-17, x. PubMed ID: 17502236
[TBL] [Abstract][Full Text] [Related]
11. Progress in HIV-1 vaccine development.
Haynes BF; Moody MA; Alam M; Bonsignori M; Verkoczy L; Ferrari G; Gao F; Tomaras GD; Liao HX; Kelsoe G
J Allergy Clin Immunol; 2014 Jul; 134(1):3-10; quiz 11. PubMed ID: 25117798
[TBL] [Abstract][Full Text] [Related]
12. Adenovirus vectors as HIV-1 vaccines: where are we? What next?
DʼSouza MP; Yang OO
AIDS; 2015 Feb; 29(4):395-400. PubMed ID: 25630039
[No Abstract] [Full Text] [Related]
13. The "STEP-wise" future of adenovirus-based HIV vaccines.
Patterson LJ
Curr Med Chem; 2011; 18(26):3981-6. PubMed ID: 21824093
[TBL] [Abstract][Full Text] [Related]
14. [Advances in the Immunogenic Design of HIV-1 Vaccine].
Zhang X; Wang T; Yu X
Bing Du Xue Bao; 2016 Jan; 32(1):88-92. PubMed ID: 27295889
[TBL] [Abstract][Full Text] [Related]
15. HIV-1 phylogenetics and vaccines.
Rolland M
Curr Opin HIV AIDS; 2019 May; 14(3):227-232. PubMed ID: 30925535
[TBL] [Abstract][Full Text] [Related]
16. Challenges in the design of a T cell vaccine in the context of HIV-1 diversity.
Tongo M; Burgers WA
Viruses; 2014 Oct; 6(10):3968-90. PubMed ID: 25341662
[TBL] [Abstract][Full Text] [Related]
17. Challenges in the development of an HIV-1 vaccine.
Barouch DH
Nature; 2008 Oct; 455(7213):613-9. PubMed ID: 18833271
[TBL] [Abstract][Full Text] [Related]
18. Protection against chronic infection and AIDS by an HIV envelope peptide-cocktail vaccine in a pathogenic SHIV-rhesus model.
Nehete PN; Chitta S; Hossain MM; Hill L; Bernacky BJ; Baze W; Arlinghaus RB; Sastry KJ
Vaccine; 2001 Dec; 20(5-6):813-25. PubMed ID: 11738745
[TBL] [Abstract][Full Text] [Related]
19. Current views on the potential for development of a HIV vaccine.
Cohen KW; Frahm N
Expert Opin Biol Ther; 2017 Mar; 17(3):295-303. PubMed ID: 28095712
[TBL] [Abstract][Full Text] [Related]
20. Heterologous envelope immunogens contribute to AIDS vaccine protection in rhesus monkeys.
Letvin NL; Huang Y; Chakrabarti BK; Xu L; Seaman MS; Beaudry K; Korioth-Schmitz B; Yu F; Rohne D; Martin KL; Miura A; Kong WP; Yang ZY; Gelman RS; Golubeva OG; Montefiori DC; Mascola JR; Nabel GJ
J Virol; 2004 Jul; 78(14):7490-7. PubMed ID: 15220422
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
